TickerFacts.

Kalaris Therapeutics, Inc. (KLRS): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

Older than the company's other figures. The latest EBITDA is for the year ended 2023-12-31, while the company's latest annual report covers the year ended 2025-12-31. Its later filings do not report Depreciation & Amortization, which EBITDA is computed from, under the concepts TickerFacts maps.

-$199.50M
Year ended 2023-12-31
2019-12-31: -$26.68M2020-12-31: -$71.24M2021-12-31: -$169.63M2022-12-31: -$170.48M2023-12-31: -$199.50M-$199.50M
2019-12-31 EBITDA (USD) 2023-12-31
Period endedEBITDAChange YoYSource filing
2023-12-31-$199.50Mn/m2025-03-07, From 2023-01-01
2022-12-31-$170.48Mn/m2024-03-15, From 2022-01-01
2021-12-31-$169.63Mn/m2023-02-15, From 2021-01-01
2020-12-31-$71.24Mn/m2022-02-10, From 2020-01-01
2019-12-31-$26.68Mn/a2021-02-12, From 2019-01-01